Positive association between the changes in chemerin and adiponectin levels after weight reduction.
OBJECTIVE
Adiponectin and chemerin have been reported their associations with insulin resistance and chronic inflammation. However, the relationship between adiponectin and chemerin themselves has not been fully elucidated. Therefore, we investigated the effects of changes in adiponectin and chemerin levels after a weight intervention.


METHODS
We recruited 136 healthy overweight or obese subjects from 2006 to 2009 and provided all participants lifestyle modification therapy with diet consultations over 16 weeks. We assigned the participants to take orlistat or sibutramine or to a no prescription group. We analyzed the data using paired t-tests, Pearson's partial correlation analysis, and stepwise multiple linear regression analysis.


RESULTS
∆ in chemerin was positively correlated with ∆ in adiponectin (r = 0.29, p < 0.01), and these trends were similar in the insulin-resistant (r = 0.35, p = 0.03) and insulin-sensitive (r = 0.27, p < 0.01) groups. In multiple regression analyses, Δadiponectin, ΔQUICKI (quantitative insulin-sensitivity check index), Δglucose, and ΔDBP were significantly associated with Δchemerin in the insulin-resistant group, and initial chemerin level, ΔQUICKI, ΔBMI (body mass index), and taking orlistat were associated with Δchemerin in the insulin-sensitive group.


CONCLUSIONS
Changes in chemerin levels were positively associated with changes in adiponectin levels. The association between these changes might be related to chemerin's dual inflammatory and anti-inflammatory effects or insulin resistance and insulin sensitivity enhancing effects, depending on the metabolic conditions. Additional studies are needed to clarify the mechanisms that underlie the effects of adiponectin and chemerin.
a Department of Family Medicine, Myongji Hospital, Seonam University, College of Medicine , Gyeonggi-do Republic of Korea.
Hyun-Young
HY
Shin
b Department of Biostatistics, Graduate School of Public Health, Yonsei University , Seoul , Korea.
Sohee
S
Park
c Department of Family Medicine, Gangnam Severance Hospital, University College of Medicine , Seoul , Korea.
Ji Won
JW
Lee
D052242:Adiponectin / Q000097:blood*; D000328:Adult; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D018925:Chemokines / Q000097:blood*; D003131:Combined Modality Therapy; D003503:Cyclobutanes / Q000627:therapeutic use; D004038:Diet, Reducing; D015444:Exercise; D005260:Female; D000070497:Healthy Lifestyle; D006801:Humans; D007333:Insulin Resistance; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood*; D007783:Lactones / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000178:diet therapy / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D000077403:Orlistat; D050177:Overweight / Q000178:diet therapy / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D055105:Waist Circumference; D015431:Weight Loss / Q000187:drug effects
C499918:ADIPOQ protein, human; D052242:Adiponectin; D019440:Anti-Obesity Agents; D001067:Appetite Depressants; D015415:Biomarkers; D018925:Chemokines; D003503:Cyclobutanes; D036341:Intercellular Signaling Peptides and Proteins; D007783:Lactones; C478630:RARRES2 protein, human; D000077403:Orlistat; C058254:sibutramine
Adiponectin; Chemerin; inflammation; insulin resistance